Onartuzumab
- Generic Name
- Onartuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1133766-06-9
- Unique Ingredient Identifier
- MS1J9720WC
- Background
Onartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02488330
- Locations
- 🇫🇷
Hopital Roger Salengro, Lille, France
🇯🇵National Hospital Organization Shikoku Cancer Center, Ehime, Japan
🇮🇹Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Torino, Piemonte, Italy
Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)
- Conditions
- Interventions
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02044601
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01974258
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT01897038
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 10
- Registration Number
- NCT01887886
A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-08-10
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 564
- Registration Number
- NCT01662869
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT01632228
- Locations
- 🇩🇪
Ärztehaus Velen, Ibbenbühren, Germany
🇨🇦McGill University; Montreal Neurological Institute; Oncology, Montreal, Quebec, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2016-09-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT01519804
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2017-01-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 185
- Registration Number
- NCT01186991
- Locations
- 🇺🇸
Can Care Assoc Med Group Inc; Beach Cities Offices, Los Angeles, California, United States
🇺🇸Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
🇺🇸St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.